Evidence reviewed: 8 November 2026. Menopause is the life stage reached after 12 consecutive months without a menstrual period when no other cause explains the absence of bleeding. The preceding perimenopausal transition may involve irregular cycles, hot flashes, disturbed sleep and changes in vaginal or urinary comfort. For many people, symptoms can be managed with menopausal hormone therapy (MHT/HRT), nonhormonal treatment or supportive measures. Appropriate hormone treatment can be highly effective, but the choice of estrogen, progestogen, route and duration must account for age, time since menopause, uterus status and personal risks [1–3].
What changes during perimenopause and menopause?
Ovarian follicular function gradually declines, with changing estradiol and progesterone production. Hormone levels fluctuate during perimenopause, so symptoms and menstrual patterns may vary from month to month. Menopause commonly occurs between approximately ages 45 and 55, but earlier or later transitions occur. Premature ovarian insufficiency (POI), occurring before 40, requires a different diagnostic and management approach [1].
For most people aged 45 or older with typical menopausal symptoms and menstrual changes, NICE recommends a clinical diagnosis without routinely measuring FSH or estradiol, because levels fluctuate and usually do not change management. Special situations—including younger patients, hormonal contraception, hysterectomy and POI—need individual evaluation [1].
Common menopause symptoms
- Vasomotor symptoms: hot flashes, night sweats, flushing and disturbed sleep.
- Menstrual changes: irregular timing, heavier or lighter bleeding during the transition.
- Genitourinary syndrome of menopause (GSM): vaginal dryness, painful intercourse, irritation and some urinary symptoms.
- Sleep and mood: interrupted sleep, irritability, anxiety or low mood in some people.
- Cognitive complaints: perceived changes in concentration or memory, which can also reflect poor sleep or other conditions.
- Longer-term effects: accelerated bone loss after menopause, along with age-related changes in cardiometabolic risk.
These symptoms have many possible causes. New heavy or unexpected vaginal bleeding, severe depression, thyroid symptoms or major sleep disturbances should not automatically be attributed to menopause without assessment.
Which treatment fits which symptom?
| Main concern | Potential evidence-based approach | Important distinction |
|---|---|---|
| Moderate/severe hot flashes or night sweats | Appropriately selected systemic estrogen-based hormone therapy is generally most effective. | Requires assessment of endometrial protection and vascular/breast risks. |
| Vaginal dryness or painful intercourse | Moisturizers, lubricants, and often low-dose local vaginal estrogen when suitable. | Local therapy has much less systemic exposure than systemic MHT. |
| Symptoms when systemic hormones are unsuitable or declined | Menopause-specific CBT, selected nonhormonal prescription treatments, cooling and sleep strategies. | Effectiveness and safety differ by treatment. |
| Bone health concerns | Exercise, calcium/vitamin D adequacy, risk assessment and selected osteoporosis medicines. | HRT may prevent bone loss but is not the only osteoporosis treatment. |
Systemic estrogen: tablets, patches, gels and sprays
Systemic estradiol may be prescribed orally or through the skin. Estrogen reduces vasomotor symptoms and can help prevent menopausal bone loss. Transdermal preparations avoid first-pass hepatic exposure and may be associated with a lower venous thromboembolism risk than some oral preparations, although the evidence differs by study and preparation [1–3].
Oral formulations include estradiol and other approved estrogen products. Transdermal formulations include patches, gels and sprays. No formulation is universally best: symptoms, convenience, skin reactions, past thrombosis, medications and local availability all matter.
Why is progestogen needed when the uterus is present?
Systemic estrogen without adequate progestogen in a person with a uterus can stimulate the endometrium and increase endometrial hyperplasia and cancer risk. Therefore, NICE recommends combined estrogen–progestogen therapy for people with a uterus, and estrogen alone after total hysterectomy in usual circumstances [1].
Options may include micronized progesterone, selected synthetic progestins or an appropriate levonorgestrel-releasing intrauterine system when specifically authorized and positioned for endometrial protection. Regimens can be sequential (often causing a withdrawal bleed) or continuous combined, based on the stage of transition and clinical aims. Not every contraceptive IUD or progestin regimen provides adequate endometrial protection for every estrogen dose.
Low-dose vaginal estrogen used for GSM is different from systemic estrogen. NICE notes that a progestogen is not routinely needed with low-dose vaginal estrogen, because systemic exposure is limited, but unexplained vaginal bleeding still requires evaluation [1].
When do the benefits of systemic hormone therapy tend to be most favorable?
The 2022 Menopause Society position statement concluded that, for most healthy symptomatic women younger than 60 or within 10 years of menopause onset, the benefit–risk ratio of hormone therapy is generally favorable for treating vasomotor symptoms and preventing bone loss [2]. Starting treatment after age 60 or more than 10 years after menopause may have a less favorable risk profile, particularly for some cardiovascular and thrombotic outcomes. These are population-level observations, not rules that replace individual assessment.
Systemic MHT should not be prescribed primarily to prevent coronary heart disease, dementia or general aging. The indication is symptom management and, in selected circumstances, bone-health or POI management [1–3].
What changed in FDA hormone-therapy warnings in 2025–2026?
On 12 February 2026, the US Food and Drug Administration approved revised labeling for six menopausal hormone-therapy products. The changes removed statements about cardiovascular disease, breast cancer and probable dementia from the prominent boxed warning for those products. The boxed warning for endometrial cancer with systemic estrogen-alone therapy was retained [3,4].
Removal from the boxed warning does not mean all risks disappeared. Information about cardiovascular and breast-cancer risk remains elsewhere in labeling, and individual benefits and harms still require counseling. The changes must not be generalized indiscriminately to every formulation or to compounded products whose safety and effectiveness have not been evaluated [3,4].
Breast cancer and clotting risks: what should patients understand?
The balance of risk varies by estrogen alone versus estrogen plus progestogen, dose, route, duration and personal history. Combined systemic HRT is associated with a duration-related increase in breast-cancer incidence in important clinical data; risks for estrogen-only therapy after hysterectomy differ and should be discussed separately. Previous breast cancer often requires specialist assessment and a nonhormonal-first approach rather than automatically starting systemic hormones [1,2].
Systemic estrogen may increase venous thromboembolism (blood-clot) risk, with the degree of risk differing by oral versus transdermal route and patient factors. An individual with previous VTE, certain thrombophilias, active liver disease or other major contraindications needs specialist advice. Unexpected chest pain, breathlessness, one-sided leg swelling or stroke-like symptoms need urgent medical attention.
Unscheduled vaginal bleeding on hormone therapy: 2026 NICE update
Vaginal spotting can occur after starting or changing systemic HRT. The April 2026 NICE update specifies that bleeding during the first six months after starting HRT, or within three months of changing the preparation or dose, should be discussed and reviewed at the usual follow-up. Unscheduled bleeding outside those timeframes warrants prompt medical advice and appropriate investigation [1].
Do not assume postmenopausal bleeding is a harmless HRT side effect. Heavy, persistent, progressive or concerning bleeding needs clinical assessment sooner, especially with risk factors for endometrial cancer.
Local vaginal estrogen and other GSM treatments
Genitourinary syndrome of menopause can cause dryness, burning, irritation and painful intercourse. Vaginal moisturizers and lubricants may help. When symptoms persist, appropriate low-dose vaginal estrogen tablets, creams, rings or other authorized preparations are often effective [1,2].
Some locations offer other treatments such as prasterone (vaginal DHEA) or ospemifene for selected symptoms. They have product-specific risks, indications and availability. Laser and energy-based “vaginal rejuvenation” procedures should not be promoted as established substitutes for evidence-based therapy without appropriate clinical evidence and regulatory review.
Nonhormonal options for hot flashes
For people who prefer to avoid hormones or cannot take them, treatments may include menopause-specific cognitive behavioral therapy, and selected prescription medicines such as fezolinetant, certain SSRIs/SNRIs, or gabapentin, depending on local approvals and individual circumstances [1,5].
Fezolinetant is a neurokinin-3 receptor antagonist used for moderate-to-severe vasomotor symptoms in eligible patients. It has important liver injury warnings and requires liver testing according to current prescribing information. It is not a hormone and not suitable for everyone. NICE’s 2026 recommendations support it when HRT is unsuitable in eligible patients [1].
Some SSRIs/SNRIs may reduce hot flashes, but are not necessarily the first-line choice when HRT is suitable. When tamoxifen is used for breast cancer, clinicians must review potential CYP2D6 drug interactions, particularly with certain antidepressants.
What about “bioidentical” and compounded hormone preparations?
Estradiol and micronized progesterone in regulated medicines can be chemically identical to human hormones. By contrast, custom-compounded “bioidentical” hormones may lack rigorous testing of dose consistency, purity, safety and efficacy. Salivary hormone testing has not been validated as a reliable way to individualize menopausal hormone doses. Prefer approved standardized products when an appropriate option exists [2].
Menopause and contraception
Perimenopause does not mean contraception is automatically unnecessary. Ovulation can occur despite increasingly irregular periods. Hormone replacement therapy is not contraceptive. People who could become pregnant should discuss when and how to stop contraception under age- and method-specific guidance, particularly if bleeding patterns are altered by hormonal methods [1].
Bone health, sleep and lifestyle
Weight-bearing and resistance exercise, adequate calcium and vitamin D, not smoking, moderating alcohol and treating sleep disorders support general health. Menopause-specific CBT can help manage distress related to hot flashes, sleep disruption and other symptoms and may complement or replace MHT according to preferences [1].
Supplements such as black cohosh, phytoestrogens and unregulated hormone mixtures have inconsistent evidence and potential interactions or toxicity. No supplement is an established replacement for appropriately indicated systemic or local hormone therapy.
Frequently asked questions
Does everyone need a blood test to confirm menopause?
No. For most people 45 or older with a typical clinical history, routine hormone testing is not needed [1].
Can someone with a uterus use estrogen alone?
Systemic estrogen alone is generally unsafe without adequate endometrial protection. Combined treatment is usually needed [1].
Did the FDA remove all hormone-therapy risks in 2026?
No. Selected boxed-warning language was revised for certain approved products, but risk information remains in labeling [3,4].
Is low-dose vaginal estrogen the same as systemic HRT?
No. Local vaginal therapy targets GSM with much lower systemic exposure and often does not require an added progestogen [1].
Should HRT be stopped after a fixed number of years?
Not necessarily. NICE recommends periodic individualized review of symptom benefit and safety; there is no universal mandatory stop date [1].
Does HRT prevent dementia or heart attacks?
It should not be prescribed for primary prevention of dementia or cardiovascular disease [1,2].
Key takeaways
Menopause care is individualized. For many healthy symptomatic people younger than 60 or within 10 years of menopause, systemic HRT may be a reasonable and effective choice. Protect the endometrium when a uterus is present, use local vaginal therapy for GSM where appropriate, and review risks rather than treating FDA labeling updates as proof of zero harm.
References
- National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated April 2026.
- The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028.
- US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. 12 Feb 2026.
- Office on Women’s Health, US Department of Health and Human Services. Hormone therapy safety: what changed in 2025 and 2026. Accessed 8 Nov 2026.
- National Institute for Health and Care Excellence. Menopause recommendations and linked 2026 technology appraisal for fezolinetant. Accessed 8 Nov 2026.
Medical disclaimer: Educational content only. Hormone therapy is a prescription decision requiring personal review of uterus status, cancer history, blood clots, cardiovascular factors, medications and symptoms. Postmenopausal bleeding or serious new symptoms need prompt medical assessment.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.